News Lilly climbs on stellar GLP-1 drug sales gain Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.
News Lilly pauses Mounjaro orders in UK ahead of price hike Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.
News Under pressure from Trump, Lilly hikes Mounjaro prices in UK Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro to bring it into parity with other European markets.
News Texas suit claims Lilly bribed providers to prescribe drugs Eli Lilly has been accused of giving illegal inducements to encourage medical providers in Texas to prescribe its medicines.
News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.